Pharma Industry News

Tecentriq withdrawn in hard-to-treat breast cancer in US

A post-marketing study failed to show benefit for patients with triple-negative breast cancer taking Tecentriq and chemotherapy

Original Article

About the author

David Miller

a pharmacist, a tech enthusiastic, who explored the Internet to gather all latest information pharma, biotech, healthcare and other related industries.

[mwai_chat window="true" fullscreen="true"]